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Abstract
Background: Malaria infects over 300 million people every year and one of the major obstacles for the eradication
of the disease is parasite’s resistance to current chemotherapy, thus new drugs are urgently needed. Quantum dot
(QD) is a fluorescent nanocrystal that has been in the spotlight as a robust tool for visualization of live cell
processes in real time. Here, a simple and efficient method using QD to directly label Plasmodium falciparum-
infected erythrocytes (iRBCs) was searched in order to use the QD as a probe in an anti-malarial drug-screening
assay.
Methods: A range of QDs with different chemical coatings were tested for their ability to specifically bind iRBCs by
immunofluorescence assay (IFA). One QD was selected and used to detect parasite growth and drug sensitivity by
flow cytometry.
Results: PEGylated-cationic QD (PCQD) was found to specifically label infected erythrocytes preferentially with late
stage parasites. The detection of QD-labelled infected erythrocytes by flow cytometry was sensitive enough to
monitor chloroquine anti-malarial toxicity with a drug incubation period as short as 24 h (EC50 = 113nM). A
comparison of our assay with another widely used anti-malarial drug screening assay, the pLDH assay, showed that
PCQD-based assay had 50% improved sensitivity in detecting drug efficacy within a parasite life cycle. An excellent
Z-factor of 0.8 shows that the QD assay is suitable for high-throughput screening.
Conclusions: This new assay can offer a rapid and robust platform to screen novel classes of anti-malarial drugs.
Background
Malaria remains a major global health problem, threaten-
ing over 300 million people and causing nearly one million
deaths annually [1]. It is still a major cause of death espe-
cially in children under five years of age and pregnant
women in areas such as sub-Saharan Africa, which bear
the greatest burden of the disease. Due to the emergence
of resistance, the rate in which the available drugs fail in
the treatment of malaria has increased. To worsen this
situation, recent reports on the emergence of resistant
strains to artemisinin-based combination therapy (ACT)
[2,3] have accelerated the urgent need of new drugs.
Recently, the CdSe/ZnS semiconductor nanocrystal
known as quantum dot (QD) has been widely used for
various bioimaging applications as well as in vitro diag-
nostics due to high photostability, large stokes shift, and
tunable narrow emission spectral characteristics [4].
These particular interesting fluorescent properties of
QDs allowed it to be used as a robust fluorophore for
labelling bacteria [5], red blood cells (RBCs) [6], various
intracellular organelles [7], genes [8,9], and proteins
[10]. In particular, Tokumasu et al [11] used antibody-
conjugated QDs to show the distinct pattern of distribu-
tion of protein and to observe erythrocyte membrane
deformation occurring during the invasion of erythro-
cytes by P. falciparum. To search for a QD that could
specifically label P. falciparum-infected RBC, a range of
QDs with different chemical coatings (-COOH, -NH2,
amino PEG, methoxy PEGs) were tested. A PEGylated
cationic QDs (PCQD), which have been successfully
implemented for cellular labelling [12], was found to
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specifically label the iRBC, particularly at late stage para-
sites. Herein, the present study shows (i) a simple and
efficient method to label P. falciparum-infected RBC
using a QD-based probe and (ii) its applicability as an
efficient probe for anti-malarial drug screening.
Methods
QD synthesis
The PCQD were prepared by ligand exchange of trioc-
tylphospine oxide (TOPO)-QD with DEDEA (dihydroli-
poic acid-2,2’-ethylenedioxy bis(ethyleneamine)) and
subsequent conjugation with N-hydroxyl succinimide
methoxy PEG2000 (NHS-mPEG2000) molecules as
reported previously [12]. In addition to the positively
charged PCQD, negatively charged QDs with chemical
coatings of carboxylated polymers (QD-COOH), amino
PEG2000 (QD-PEG-NH2), methoxy PEG2000 (QD-
mPEG) were also prepared using polymer-coating
method with some modifications [13,14]. See Additional
file 1 for the detailed synthetic procedures and charac-
terization methods of QDs.
Plasmodium falciparum culture
Plasmodium falciparum 3D7 strain was maintained in
vitro in human O+ erythrocytes at 3% haematocrit in
RPMI 1640 media supplemented with L-glutamine, 25
mM HEPES and sodium bicarbonate. Additionally, 0.5%
Albumax I, 0.1 mM hypoxanthine and 16 μM thymidine
were added to complete the media. To obtain a syn-
chronized culture, the parasites were submitted to two
sequential 5% sorbitol treatments that were 10 hours
apart, cultivated for an additional 30 hours, allowed to
re-invade RBCs and then used for experiments at 10-15
hours post-invasion (hpi) for young-stage parasites and
at 30-35 hpi for late-stage parasites.
Fluorescence image acquisition
Synchronized young and late stage parasites were incu-
bated with PCQD and Hoechst (RBC: PCQD: Hoechst =
5 × 107 cells: 2 μM: 5 μM) for 1 h at 37°C with gentle
shaking. Parasites were then washed once with PBS and
transferred to glass slides (Cell-line/Erie Scientific Co,
US) for image acquisition. Image acquisition was per-
formed on Epifluorescence microscope (Eclipse 90i,
Nikon, Japan) using synchronized parasites.
Flow cytometry
To determine the sensitivity of PCQD in detecting dif-
ferent levels of parasitemia, synchronized late-stage
parasites were serially diluted with fresh RBC and ana-
lysed in a Flow cytometer FACSCanto II (BD, USA). For
the procedure, cells were fixed with 2% paraformalde-
hyde + 0.008% glutaraldehyde solution for 30 min,
washed once in PBS and stained with PCQD and
Hoechst as described for the image acquisition experi-
ments. The cells in the gate of both PCQD and Hoechst
positive were only counted for data analysis. As a con-
trol, slides using the same serially diluted samples were
prepared, stained with Giemsa (Merck) and counted
manually using a light microscope.
Dose-response curve of chloroquine
Dose-response experiments (range 0.45 nM to 1 μM)
were carried out in 96-well plate at 0.5% and 10% para-
sitaemia (for 60 h and 24 h drug-exposure, respectively)
of synchronized parasites (young stage) at 2% haemato-
crit, 37°C, in triplicates. After the drug exposure, the
cells were fixed and stained as already described. Data
analysis was performed using FACSDiva Software (BD,
USA). The data were normalized using average result of
chloroquine-treated wells (at EC100 concentration) and
average result of non-treated wells as 0% and 100%,
respectively.
For the pLDH assay, the same conditions were used
but culture was added to 384-well plate (Greiner). After
the drug exposure time was finished, the plates were
frozen overnight at -20°C. After thawing, the plates were
shaken for 45 sec at 1700 rpm in Mix Mate (Eppendorf)
and 5 μL of the lysate was transferred into the corre-
spondent well of another plate containing 30 μL of Mal-
stat Reagent [15] and incubated for 2 h. The absorbance
(650 nm) was read at Spectramax M5 (Molecular
Devices, USA).
Results
Specificity and sensitivity of PCQD for detecting P.
falciparum-infected erythrocytes
A panel of QDs with different chemical coatings (QD-
COOH, QD-PEG-NH2, QD-mPEG, and PCQD) were
characterized with regard to their hydrodynamic sizes,
charges, and quantum yield (Table 1). These well-
defined QDs with different charges and sizes were
visually screened for their ability to bind iRBCs, and
PCQD was found to bind P. falciparum-infected ery-
throcytes (Figure 1). However, this PCQD was only able
to bind mature asexual stage-iRBCs, i.e., the pigment-
bearing trophozoites and schizonts, and not young
stage-iRBCs. The quality of the labelling (signal to noise
ratio) was enough for clear identification of positives
and quantitatively, 60% of the infected erythrocytes were
PCQD-positive.
To verify its labelling sensitivity, synchronized late-
stage parasites were serially diluted to achieve a linear
curve of parasitaemia and incubated with PCQD and
the DNA staining Hoechst for labelling. The number of
PCQD-labelled cells was measured by flow cytometry
and, indeed, decreased proportionally as the number of
the parasites was diminished, confirming that PCQD
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was specifically binding to iRBCs. In agreement with
these findings, a high linear correlation (R2 = 0.9152)
was observed between cytometry data and manual
assessment of parasitaemia from Giemsa-stained smears
for each dilution point (Figure 2A).
PCQD as a probe in chloroquine dose-response assay for
60 h drug exposure
The specific binding of PCQD to infected RBCs
prompted us to setup an assay for anti-malarial drug
screening using PCQD as a fluorescent probe. Early
stages synchronized P. falciparum cultures at low parasi-
taemia were incubated in triplicates with serially diluted
concentrations of chloroquine to obtain a dose-response
curve (DRC). To compare PCQD assay with the pLDH
assay, a well-known anti-malarial drug-screening assay,
the same cultures were prepared in 384-well plate in
parallel. After 60 hours of drug exposure, the cultures
from each plate were developed by PCQD assay and
pLDH assay as described in Methods. The DRC of
chloroquine from both assays showed EC50s of 26 nM,
in accordance with reported values using other assays
(Figure 2B) [16]. In addition, the Z-factor calculated for
the PCQD assay was 0.8, which is high enough to enable
assay automation and high-throughput screening.
PCQD as a probe in chloroquine dose-response assay for
24 h drug exposure, within a single asexual cycle
Chloroquine exerts its plasmocidal effects only on
mature stages of the asexual cycle [16]. Thus we further
tested if PCQD would be sensitive enough to detect
chloroquine effects on parasite viability within a single
Table 1 Molecular characteristics of QDs used in this study
Sample code Hydrodynamic size (nm)a) Zeta potential (mV)b) Quantum Yieldc)
PCQD 10 ± 0.8 20 ± 3 0.1
QD-COOH 10 ± 1.2 - 33 ± 6 0.2
QD-PEG-NH2 13 ± 1.8 -25 ± 5 0.2
QD-mPEG 12 ± 1.3 - 8 ± 1 0.2
a) Number-averaged diameter measured using dynamic light scattering instrument (n = 3), b) average of three measurements in water, and c) compared with
fluorescein (quantum yield = 0.95).
Figure 1 Quantum dot (QD) labelling on P. falciparum-infected erythrocytes showing that only late-stage iRBCs are labelled. Early-stage
(ring) iRBCs (A) are not labelled by the QD, while the late-stage trophozoite (B) and segmented schizont (C) iRBCs are both labelled. The
parasites were stained with Hoechst 33324 (in red, first column from the left) and PCQD (in green, second column). Phase contrast images (third
column) and merged images (fourth column) are also shown. Bars, 5 mm.
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asexual cycle (i.e., without changes in the parasitaemia).
Synchronized early stage parasites at high parasitaemia
(10%) were incubated for 24 h with serial dilutions of
chloroquine followed by flow cytometry analysis. The
DRC-derived EC50 was 113 nM, which was also compar-
able with previous reports (Figure 2C) [16]. A paralleled
pLDH assay was also performed and compared with
PCQD assay, showing PCQD-based assay was signifi-
cantly more sensitive in detecting drug efficacy within a
parasite life cycle than in the pLDH assay; at 100 nM
chloroquine, PCQD assay detected 53%(±19) while
pLDH assay showed 0%(±8) of growth inhibition (p =
0.0024, two tailed t-test).
Discussion
QDs have been largely applied in conjugation with var-
ious biomolecules including DNA oligonucletides, pep-
tides, and antibodies due to their properties such as
photostability and narrow emission spectra [17,18]. In
this work, a range of different QDs were screened for
labelling the iRBC to use it as a probe in an assay to
search for anti-malarial drugs. This straightforward
strategy of searching for a QD that could by itself speci-
fically label P. falciparum iRBC shortened the assay
development time, sparing us, for example, from the
development and characterization of an antibody against
parasite-specific protein and antibody-QD conjugation
processes.
The QDs used for this study include various surface
coatings with different charges (positive or negative),
PEG molecules (with or without), and functional groups
(carboxyl or amine). Out of the various QDs tested, only
PCQD with a positive and PEGylated coating could
interact specifically with late stage parasitized RBCs.
Although the nature of the interaction between the
PCQD and the iRBC is yet not clear, the fact that nega-
tively charged QD did not label RBC infected with late
stage parasites suggests that the positive charge might
be important for this interaction. In this sense, positively
charged QD has been known to facilitate the binding
with cellular membrane via electrostatic interaction. The
PCQD originally developed in our lab has strong posi-
tive charge in the surface with high positive zeta poten-
tial value and this positive charge seemed to promote
the interaction with the cell membrane [10,12]. In addi-
tion, given (i) the surface pattern of the labelling
observed, (ii) the size of the PCQD that does not allow
for free diffusion across the membrane and (iii) the
absence of endocytosis in red blood cells it is likely that
the interaction between PCQD and the iRBC takes place
only at the cell’s surface although the target(s) for this
interaction remains unknown.
The specific labelling of infected RBCs by PCQD
prompted us to test if the PCQD could be used as a
probe to determine drug efficacy. The PCQD-based
assay was able to detect successfully the effect of chloro-
quine not only in 60 h but also in 24 h, within a parasite
life cycle, with 50% more sensitivity than pLDH assay.
The PCQD assay can provide an alternative, rapid and
efficient method for screening fast-acting anti-malarial
drugs because of its ability to detect the plasmocidal
effects of a drug within a single erythrocytic cycle. Its
cost, comparable to that of pLDH assay, makes it acces-
sible to practically all academic set-ups and its perfor-
mance (z’ = 0.8) enable for high-throughput setting as
well. Furthermore, due to the PCQD’s exclusive labelling
Figure 2 Validation of PCQD as a tool for P. falciparum drug discovery. (A) Comparison of QD detection of increasing P. falciparum
parasitaemia assessed by flow cytometry and manually from Giemsa-stained culture smears. The late-stage P. falciparum culture was serially diluted
and incubated with PCQD and Hoechst and analyzed by flow cytometry. The plot shows the correlation (R2 = 0.9152) of the parasitaemia values
detected by both methods. (B) Comparison of chloroquine DRCs using PCQD and pLDH assays. Synchronized young parasites were incubated with
increasing concentrations of chloroquine. After 60 h of incubation, samples were either fixed and labelled with PCQD and Hoechst for PCQD assay
or developed for the pLDH assay as described above. The plot shows a consistent EC50 of 26 nM for both assays. (C) The chloroquine DRC of a 24-h
drug exposure within a single erythrocytic cycle using the PCQD assay. The DRC-derived EC50 was 113 nM.
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of late-stage parasites, this assay may be a powerful tool
to look for specific drugs interfering in the maturation
of parasites. This possibility is currently under
investigation.
Conclusions
Although the mechanism of specific labelling of parasi-
tized RBC at the late stage with the PCQD has to be
further elucidated, the ability of the PCQD to label the
live parasitized RBC with high photostability led us to
develop a rapid and efficient assay to screen anti-plas-
modial compounds, setting a platform to search novel
anti-malarial drugs.
Additional material
Additional file 1: QD synthesis and characterization. Detailed
explanation of QD synthesis and methods used for their characterization
as seen in Table 1.
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